Upon treatment with Ful, IGFBP-3 was induced in breast cancer cells similar to data observed in reports describing the regulation of IGFBP-1 by the G-protein-coupled estrogen receptor (GPER1) and clinical studies showing IGFBP-3 serum increases in response to Ful (17–19). The gene discussed is IGFBP1; the disease is breast carcinoma.